Lincoln Capital Corp’s CRISPR Therapeutics CRSP Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,000	Closed	-$204K	–	85
2024 Q1	$204K	Buy	+3,000	New	+$204K	0.09%	70
2023 Q4	–	Sell	-4,500	Closed	-$204K	–	78
2023 Q3	$204K	Buy	+4,500	New	+$204K	0.11%	71